Investing in Emerging Innovations
iAccess Alpha Conference Spotlights High-Growth Small Caps in Biotech, AI, and Advanced Manufacturing
Key Points
RenovoRx is already adopted at 16 active centers as of May 2026, with interim data showing a six-month survival improvement and a 65% reduction in toxicities versus standard of care.
RenovoRx projects gross margins of 85–90% and operating margins above 30%, supported by a $12.4 million cash balance at the end of Q1 2026 to fund operations into 2027.
Amaero’s PM‑HIP titanium and refractory powder production uses about half the argon gas of competitors and benefits from subsidized electricity in Tennessee, with 75% of planned refractory production contracted and multiple defense-related customers including Navy programs.
Rank One Computing reports a speed advantage for its ROC platform, with NIST benchmarking showing 15-second searches versus 90 minutes for incumbents, highlighting real-time video intelligence and biometric capabilities with multi-year contract potential.
BOS Better Online Solutions has delivered 21 consecutive profitable quarters, posting 2025 revenue of $51 million and 80% of revenues being predictable from defense-related segments across its three divisions (supply chain, RFID, and robotics).
Four small-cap companies took center stage at the iAccess Alpha Virtual Best Ideas Summer Investment Conference on June 23, 2026, pitching investors on everything from cancer-fighting catheters to titanium powder for hypersonic missiles. The event, which runs through June 24, pairs company presentations with one-on-one investor meetings designed to bridge the funding gap that plagues micro-cap firms. Seeking Alpha covered the sessions live.
The lineup spans three fast-growing sectors: targeted oncology, advanced manufacturing, and sovereign AI. Each company is making a case that it has moved past the concept stage and into real revenue, with defensible margins to match.
RenovoRx Posts Survival Gains With 85% Gross Margins
RenovoRx is selling a device called RenovoCath, a catheter that delivers chemotherapy directly to a tumor instead of through the bloodstream. The approach cuts systemic toxicities by 65% compared to standard IV treatment, according to interim data from the company's TIGeR-PaC trial. CEO Shaun Bagai called it a "high-margin business model," and the numbers back that up: gross margins sit at 85–90%, with operating margins projected above 30%. The company had $12.4 million in cash at the end of Q1 2026, enough to fund operations into 2027, per Quartr.
Adoption is climbing fast. RenovoRx confirmed 16 active cancer centers as of May 2026, up from just a handful a year earlier, with 32 more in the pipeline. The company targets locally advanced pancreatic cancer, a disease where standard chemotherapy often fails because the tumor has poor blood flow. If the Phase III trial data holds, analysts say the company could reach breakeven by 2027.
Amaero Bets Tennessee Titanium Powder on Defense Demand
Amaero Ltd. is relocating from Australia to McDonald, Tennessee, to produce titanium and refractory metal powders for defense and aerospace customers. The company uses a process called PM-HIP — powder metallurgy hot isostatic pressing — that uses roughly half the argon gas of competitors. A 10-year subsidized electricity contract at about $0.058 per kilowatt-hour, roughly 70% below the U.S. national average, keeps costs low. Chairman Hank Holland said the U.S. "wants secure, local production of critical alloys." Quartr reported the company commissioned its third advanced atomizer in June, ahead of schedule.
The timing is deliberate. Refractory metals like C103 and tantalum go into hypersonic missiles and nuclear reactors — parts the Pentagon cannot source from adversaries. Amaero already has Navy contracts in place, and 75% of its planned refractory production is under contract. A U.S. IPO is planned for late 2026 or early 2027, giving investors a direct stake in domestic defense supply chain capacity.
Rank One Computing Searches 30 Million Faces in 15 Seconds
Rank One Computing, which completed its Nasdaq IPO in February 2026, builds AI tools for law enforcement and border security — facial recognition, fingerprint matching, and video search, all from one platform. The speed gap versus older systems is striking. NIST benchmarking shows ROC's platform searches 30 million people in 15 seconds. Legacy systems take 90 minutes for the same task, according to Quartr. CEO Scott Swann warned against the "dangerous overreliance on foreign AI" in national security and positioned ROC as the domestic alternative.
ROC ranked number one globally for NIST fingerprint accuracy in May 2026. The company is shifting customers toward multi-year contracts, which builds predictable recurring revenue. A federal policy push requiring agencies to phase out AI from foreign adversaries is opening doors that were previously locked by entrenched incumbents like IDEMIA and Thales.
BOS Better Online Solutions Logs 21 Straight Profitable Quarters
BOS Better Online Solutions runs three businesses: defense supply chain, RFID tracking, and robotics. The company posted $50.6 million in 2025 revenue and has been profitable for 21 consecutive quarters as of Q1 2026, per Seeking Alpha. CEO Eyal Cohen said 80% of revenues are predictable, with defense-related segments driving "robust demand." The company raised its 2026 guidance above $51 million after its backlog grew 29% to $31 million earlier this year.
BOS trades at roughly 9 to 11 times earnings — well below the Russell 2000 average of 22 times. Management is betting that conferences like iAccess Alpha can close that valuation gap by putting the company's consistency in front of more institutional investors. The defense tilt gives the business a buffer that purely commercial supply chain firms do not have.
Sentiment
Mostly PositivePublishers
11
Articles
81
Reach
92
